A judicial magistrate here Tuesday granted three-day remand of owners of pharmaceutical companies to Federal Investigation Agency for interrogation about alleged bogus medicines that caused several deaths in Punjab Institute of Cardiology.
Earlier, the agency sought 10-day remand of the accused, but the magistrate allowed only three days custody of the accused Tahir Azam, Chaudhry Nadir and Muhammad Wasim.The prosecution counsel argued before the court that at-least 65 patients had died while hundreds of others were affected after using medicines supplied by these companies.
The counsel said the medicines supplied by the companies were substandard while manufacturing and expiry dates were also not mentioned on them.On the other hand, counsel for the accused argued that the federal government took action against his clients in haste only to gain political mileage.
He said the federal government jumped into the provincial matter unnecessarily and without having any evidence against the companies.
The counsel alleged that the patients died due to negligence on part of doctors but the whole responsibility was being shifted to pharmaceutical companies.
Earlier, the agency sought 10-day remand of the accused, but the magistrate allowed only three days custody of the accused Tahir Azam, Chaudhry Nadir and Muhammad Wasim.The prosecution counsel argued before the court that at-least 65 patients had died while hundreds of others were affected after using medicines supplied by these companies.
The counsel said the medicines supplied by the companies were substandard while manufacturing and expiry dates were also not mentioned on them.On the other hand, counsel for the accused argued that the federal government took action against his clients in haste only to gain political mileage.
He said the federal government jumped into the provincial matter unnecessarily and without having any evidence against the companies.
The counsel alleged that the patients died due to negligence on part of doctors but the whole responsibility was being shifted to pharmaceutical companies.
No comments:
Post a Comment